Specifically, they found that HOXA5 was significantly upregulated in MS patients through individual transcriptomic (ARCHS4 database [56]) and proteomic analysis (BioGrid [210]) and that HOXA5 was found to promote the transforming growth factor (TGF)-beta pathway [189]. This evidence concerns the gene HOXA5 and myeloid sarcoma.